Browse the evidence

Aerobic conditioning (AC) prior to resistance training (RT) increases type I, type II, and mixed-fiber cross-sectional area (CSA) in healthy young men and women.

Incorporating aerobic conditioning before resistance training may enhance muscle growth.

Aerobic conditioning prior to resistance training increases satellite cell (SC) content, activation, and differentiation.

Enhancing SC content through aerobic conditioning may improve muscle adaptation to resistance training.

The oral formulation of semaglutide reduced AF incidence by 52%.

The oral formulation of semaglutide may be particularly effective in reducing AF risk.

Tai Chi exercise therapy significantly decreases fasting blood glucose (FBG) by an average of 0.79 mmol/L in patients with type 2 diabetes mellitus (T2DM).

Incorporating Tai Chi into exercise prescriptions may help lower blood glucose levels in T2DM patients.

Tai Chi exercise therapy significantly decreases glycated hemoglobin (HbA1c) by an average of 1.10% in patients with T2DM.

Tai Chi may be an effective intervention for improving long-term glucose control in T2DM patients.

Participants treated with SAR425899 lost more weight, fat mass, and fat free mass compared to those on placebo (p < 0.05).

SAR425899 may enhance weight loss and body composition improvements.

Semaglutide use is effective in patients with IBD and obesity, resulting in a mean weight loss of over 5%.

Clinicians can consider semaglutide as a viable weight loss option for patients with IBD and obesity.

Functional foods rich in bioactive compounds can mitigate oxidative stress and inflammation post-exercise.

Incorporating functional foods into recovery nutrition can enhance recovery by reducing inflammation.

Personalized nutrition informed by genetic and metabolic profiling is a promising approach to tailor recovery strategies.

Tailoring recovery nutrition based on individual profiles can enhance recovery outcomes.

Semaglutide is associated with weight loss in adults.

Practitioners can consider semaglutide as a treatment option for weight loss in adults with type 2 diabetes or obesity.

Semaglutide improves control of diabetes in adults.

Practitioners can utilize semaglutide to enhance diabetes management in adults.

Plant-based dietary patterns rich in minimally processed foods, vegetables, and fruits reduce CVD risk.

Health professionals should recommend plant-based diets rich in whole foods to reduce CVD risk.

The Mediterranean, Dietary Approaches to Stop Hypertension, and vegetarian diets reduce CVD risk.

Health professionals should promote these specific dietary patterns to lower CVD risk.

GLP-1 receptor agonists (GLP-1 RA) are a safe and effective treatment for weight regain and insufficient weight loss after metabolic bariatric surgery.

Practitioners can consider GLP-1 RA as a viable option for patients struggling with weight management post-surgery.

Weekly semaglutide leads to significantly greater weight loss compared to daily liraglutide.

Clinicians may prefer semaglutide over liraglutide for enhanced weight loss outcomes.

Women on hormone therapy (HT) had a higher total body weight loss percentage (TBWL%) at 3, 6, 9, and 12 months compared to women not on HT.

Practitioners may consider hormone therapy as a factor in weight loss strategies for postmenopausal women.

A greater percentage of women on HT achieved ≥5% and ≥10% total body weight loss at 12 months.

This suggests that hormone therapy may enhance the effectiveness of weight loss treatments.

Exercise is a key component of nonalcoholic fatty liver disease (NAFLD) treatment.

Practitioners should incorporate exercise into treatment plans for NAFLD.

Exercise training modulates fatty acid metabolism, reduces hepatic inflammation, and improves liver fibrosis.

Exercise should be tailored to target these specific metabolic and inflammatory pathways.

The effectiveness of exercise in improving NAFLD is influenced by exercise type, intensity, and volume.

Exercise programs should consider these factors to optimize treatment outcomes.

ω-3-PL/FFA reduced triglyceride (TG) levels by 26.0% at 12 weeks compared to 15.1% in the placebo group.

Practitioners can consider ω-3-PL/FFA as an effective option for lowering TG levels in patients with severe hypertriglyceridemia.

Tirzepatide administration for 72 weeks elicited significant weight reduction ranging from 5% to 20.9% across different trials in a dose-dependent manner.

Tirzepatide may be an effective option for weight management in patients with obesity and T2DM.

Tirzepatide significantly decreased food intake and reduced overall appetite scores.

Tirzepatide may help reduce appetite, aiding in weight loss efforts.

Tirzepatide exhibited favorable effects on glycemic control, with reductions in HbA1c levels ranging from 20.4 mmol/mol with the 5 mg dose to 28.2 mmol/mol with the 15 mg dose.

Tirzepatide may improve glycemic control in patients with T2DM.